ganaxolone
Commercial- Indications
- CDD, Status Epilepticus, Tuberous Sclerosis Complex, Lennox Gastaut Syndrome
Company intelligence / Profile preview
Tenacia Biotechnology
Shanghai, Shanghai, Chinabaincapitallifesciences.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Tenacia is advancing multiple programs including ganaxolone (approved in US for CDKL5 Deficiency Disorder), ulixacaltamide (IND Application for Essential Tremor), and DNTH-103 (IND Application for Autoimmune Diseases)
- Therapeutic areas
- PsychiatryImmunologyNeurology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Marinus PharmaceuticalsPraxis Precision MedicinesInsilico MedicineZenas BioPharma
Beyond the preview
Go deeper on Tenacia Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenacia Biotechnology.